Innoviva Management
Management criteria checks 3/4
Innoviva's CEO is Pavel Raifeld, appointed in May 2020, has a tenure of 5.75 years. total yearly compensation is $2.72M, comprised of 18.5% salary and 81.5% bonuses, including company stock and options. directly owns 0.019% of the company’s shares, worth $324.49K. The average tenure of the management team and the board of directors is 2.3 years and 8 years respectively.
Key information
Pavel Raifeld
Chief executive officer
US$2.7m
Total compensation
| CEO salary percentage | 18.53% |
| CEO tenure | 5.8yrs |
| CEO ownership | 0.02% |
| Management average tenure | 2.3yrs |
| Board average tenure | 8yrs |
Recent management updates
Recent updates
Innoviva's (NASDAQ:INVA) Solid Profits Have Weak Fundamentals
Nov 13
Innoviva, Inc.'s (NASDAQ:INVA) Shares Bounce 26% But Its Business Still Trails The Market
Nov 12We Think Innoviva (NASDAQ:INVA) Can Manage Its Debt With Ease
Sep 11Innoviva, Inc. Just Recorded A 54% EPS Beat: Here's What Analysts Are Forecasting Next
Aug 09Innoviva, Inc.'s (NASDAQ:INVA) Low P/S No Reason For Excitement
Jun 23Innoviva: A Riddle Wrapped In A Mystery Inside An Enigma
Jun 08Innoviva: Underappreciated Strength In Hospital Therapeutics
Feb 23Innoviva, Inc.'s (NASDAQ:INVA) Popularity With Investors Is Under Threat From Overpricing
Dec 19Benign Growth For Innoviva, Inc. (NASDAQ:INVA) Underpins Its Share Price
Jul 26Innoviva: Potentially Overvalued
Jun 21Why Innoviva's (NASDAQ:INVA) Shaky Earnings Are Just The Beginning Of Its Problems
May 21Here's Why Innoviva (NASDAQ:INVA) Can Manage Its Debt Responsibly
Feb 05Is Innoviva (NASDAQ:INVA) A Risky Investment?
Nov 04Innoviva (NASDAQ:INVA) Seems To Use Debt Quite Sensibly
Mar 02Innoviva Stock? Not Yet. Short Puts? Definitely.
Sep 19Does Innoviva (NASDAQ:INVA) Have A Healthy Balance Sheet?
Sep 19Does Innoviva (NASDAQ:INVA) Have A Healthy Balance Sheet?
Jun 16Continuing To Avoid Innoviva Inc.
Jun 07We Think Innoviva (NASDAQ:INVA) Can Manage Its Debt With Ease
Mar 04Taking Innoviva Winnings Off The Table, Again
Feb 21Innoviva Inc.: Short Puts Are Compelling
Jan 15Is Innoviva (NASDAQ:INVA) A Risky Investment?
Oct 19Taking Profits In Innoviva Inc.
Oct 16These 4 Measures Indicate That Innoviva (NASDAQ:INVA) Is Using Debt Safely
Mar 30Is Weakness In Innoviva, Inc. (NASDAQ:INVA) Stock A Sign That The Market Could be Wrong Given Its Strong Financial Prospects?
Mar 04Did Innoviva's (NASDAQ:INVA) Share Price Deserve to Gain 36%?
Jan 15These 4 Measures Indicate That Innoviva (NASDAQ:INVA) Is Using Debt Safely
Dec 25
Will Weakness in Innoviva, Inc.'s (NASDAQ:INVA) Stock Prove Temporary Given Strong Fundamentals?
Dec 04CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2025 | n/a | n/a | US$127m |
| Jun 30 2025 | n/a | n/a | US$39m |
| Mar 31 2025 | n/a | n/a | -US$60m |
| Dec 31 2024 | US$3m | US$503k | US$23m |
| Sep 30 2024 | n/a | n/a | US$65m |
| Jun 30 2024 | n/a | n/a | US$145m |
| Mar 31 2024 | n/a | n/a | US$181m |
| Dec 31 2023 | US$869k | US$485k | US$180m |
| Sep 30 2023 | n/a | n/a | US$50m |
| Jun 30 2023 | n/a | n/a | US$233m |
| Mar 31 2023 | n/a | n/a | US$233m |
| Dec 31 2022 | US$2m | US$440k | US$214m |
| Sep 30 2022 | n/a | n/a | US$293m |
| Jun 30 2022 | n/a | n/a | US$99m |
| Mar 31 2022 | n/a | n/a | US$188m |
| Dec 31 2021 | US$1m | US$391k | US$266m |
| Sep 30 2021 | n/a | n/a | US$309m |
| Jun 30 2021 | n/a | n/a | US$265m |
| Mar 31 2021 | n/a | n/a | US$253m |
| Dec 31 2020 | US$2m | US$222k | US$224m |
Compensation vs Market: Pavel's total compensation ($USD2.72M) is below average for companies of similar size in the US market ($USD5.20M).
Compensation vs Earnings: Pavel's compensation has increased by more than 20% in the past year.
CEO
Pavel Raifeld (41 yo)
Mr. Pavel Raifeld, CFA, is Director of Syndeio Biosciences, Inc. He is a Director of La Jolla Pharmaceutical Company since August 22, 2022. He serves as Chief Executive Officer of Innoviva, Inc. since May...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 5.8yrs | US$2.72m | 0.019% $ 324.5k | |
| Chief Financial Officer | 2.5yrs | US$1.01m | 0.0037% $ 61.9k | |
| Chief Accounting Officer & Secretary | 7.6yrs | US$967.32k | 0.065% $ 1.1m | |
| Chief People Officer | less than a year | no data | no data | |
| Chief Commercial Officer-Innoviva Specialty Therapeutics | 1.6yrs | no data | no data | |
| Chief Medical Officer of IST | 2yrs | no data | no data |
Experienced Management: INVA's management team is considered experienced (2.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | no data | US$2.72m | 0.019% $ 324.5k | |
| Independent Director | 8yrs | US$401.16k | 0.17% $ 2.9m | |
| Independent Director | 3.1yrs | US$376.16k | 0.040% $ 677.0k | |
| Independent Director | 1.8yrs | US$481.90k | 0.026% $ 429.7k | |
| Independent Director | 8.2yrs | US$341.16k | 0.15% $ 2.4m | |
| Independent Director | 8yrs | US$392.03k | 0.16% $ 2.7m | |
| Independent Chairman | 8yrs | US$380.29k | 0.16% $ 2.7m |
Experienced Board: INVA's board of directors are considered experienced (8 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/02/13 19:43 |
| End of Day Share Price | 2026/02/13 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Innoviva, Inc. is covered by 18 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jon Langenfeld | Baird |
| James Birchenough | Barclays |
| Patrick Trucchio | Berenberg |